

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       |                                    |                                                     |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------------|---------------------------------------|------------------------------------|-----------------------------------------------------|--|
| <b>REPORT DOCUMENTATION PAGE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |             |                       |                                       |                                    | <i>Form Approved<br/>OMB No. 0704-0188</i>          |  |
| <small>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</small> |             |                       |                                       |                                    |                                                     |  |
| <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |             |                       |                                       |                                    |                                                     |  |
| <b>1. REPORT DATE (DD-MM-YYYY)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             | <b>2. REPORT TYPE</b> |                                       |                                    | <b>3. DATES COVERED (From - To)</b>                 |  |
| <b>4. TITLE AND SUBTITLE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |             |                       |                                       | <b>5a. CONTRACT NUMBER</b>         |                                                     |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       | <b>5b. GRANT NUMBER</b>            |                                                     |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       | <b>5c. PROGRAM ELEMENT NUMBER</b>  |                                                     |  |
| <b>6. AUTHOR(S)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                       |                                       | <b>5d. PROJECT NUMBER</b>          |                                                     |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       | <b>5e. TASK NUMBER</b>             |                                                     |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       | <b>5f. WORK UNIT NUMBER</b>        |                                                     |  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |             |                       |                                       |                                    | <b>8. PERFORMING ORGANIZATION<br/>REPORT NUMBER</b> |  |
| <b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |                       |                                       |                                    | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>             |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                       |                                       |                                    | <b>11. SPONSOR/MONITOR'S REPORT<br/>NUMBER(S)</b>   |  |
| <b>12. DISTRIBUTION/AVAILABILITY STATEMENT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |                       |                                       |                                    |                                                     |  |
| <b>13. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |                       |                                       |                                    |                                                     |  |
| <b>14. ABSTRACT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                       |                                       |                                    |                                                     |  |
| <b>15. SUBJECT TERMS</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |                       |                                       |                                    |                                                     |  |
| <b>16. SECURITY CLASSIFICATION OF:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |                       | <b>17. LIMITATION OF<br/>ABSTRACT</b> | <b>18. NUMBER<br/>OF<br/>PAGES</b> | <b>19a. NAME OF RESPONSIBLE PERSON</b>              |  |
| a. REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | b. ABSTRACT | c. THIS PAGE          |                                       |                                    | <b>19b. TELEPHONE NUMBER (Include area code)</b>    |  |



**59th Medical Wing**  
**Institutional Animal Care and Use Committee (IACUC)**  
59 Clinical Research Division/SGVUS  
1100 Wilford Hall Loop, Bldg 4430  
Lackland AFB, TX 78236-5300

**NOTICE OF ACTION REGARDING IACUC REVIEW**

**Date: 2 Mar 18**

**TO: Maj Joseph Maddry/SGO3D**

Your **Final Report** was reviewed by the WHASC IACUC during the 13 Feb 18 meeting. The Committee's decision is provided below:

**FWH20140070A**, "Intravenous versus intramuscular // compared to intravenous saline (control) in the treatment of acute, survivable, hydrogen sulfide toxicity in swine (Sus Scrofa)." **PI: Maj Joseph Maddry/59 EMDS/SGO3D**

The committee voted that this item be **approved** as written. **FOLLOW-UP: CLOSED**

**Name of Official**  
MARIA E. DOMINGUEZ

**Title/Office Symbol/Phone**  
Office of Research Protocol Support /SGVUS 292-6095

**Signature**

**Info Copy To**

**1. Protocol Number: FWH20140070A****2. Type of Research:** Animal Research

**3. Title:** Intravenous versus intramuscular cobinamide compared to intravenous saline (control) in the treatment of acute, survivable, hydrogen sulfide toxicity in swine (Sus Scrofa).

**4. Principal Investigator (PI):**

| Name          | Rank | Date of IACUC Training | Branch of Service/ Corps | Staff Resident Fellow Civilian | Department / Office Symbol | Email (if other than WHASC Outlook) | Phone        | Pager           |
|---------------|------|------------------------|--------------------------|--------------------------------|----------------------------|-------------------------------------|--------------|-----------------|
| Joseph Maddry | O-4  | Jul 2015               | USAF                     | Staff                          | 59 <sup>th</sup> EMDS      | Joseph.maddry@gmail.com             | 210-916-3693 | CP 210-630-7374 |

**5. Purpose:** This novel, reproducible model of hydrogen sulfide toxicity was developed to test drug treatments and/or resuscitation treatments that reverse the toxicity. To date there are no reproducible models of hydrogen sulfide toxicity although hydrogen sulfide toxicity is reported to be one of the leading causes of unintentional workplace gas inhalation deaths. Newer methods of extracting oil and gas such as hydraulic fracturing produce excessive levels of hydrogen sulfide gas. Hydrogen sulfide could also be used as a terrorist weapon in confined areas. There are no published reports indicating that a reproducible, lethal but survivable model of hydrogen sulfide toxicity have been developed. This model provides the ability to test any number of antidotes, drugs, or resuscitative measures in the treatment of hydrogen sulfide toxicity.

**6. Results:**

At the beginning of the study we had an unanticipated set back with the IM Cobinamide arm; we had difficulty resuscitating them despite varying the dose and timing of the Cobinamide. We shifted our focus to the IV arm. The NaHS was infused until the animal reached apnea, then titrated down twice and remained on 0.1mg/kg/min for the remainder of the study. Animals were treated with IV HOC, IV Cobinamide or control (no treatment) 1 minute post apnea. There were no significant differences in baseline variables. All of the IV Cobinamide treated animals survived, compared to IV HOC and control. Mean time to spontaneous ventilation in the Cobinamide treated animals was 3.2 minutes.

After completion of our IV arm we moved back to the IM model. We collaborated with Dr. Bebart, under CRADA 16-206-AFMS59-C16004, at the University of Colorado, Denver, to complete the IM portion of the protocol. There were no significant differences in baseline hemodynamics and arterial blood gases were normal in both groups. There were no significant differences in the mg/kg dose of NaHS required to produce apnea or MAP less than 45 mmHg (9.04±6.16 mg/kg cobinamide vs. 5.90±5.54mg/kg control; 95% CI of difference 11.32, -5.04). All of the cobinamide treated animals survived (5/5), none of the control (0/6) animals survived. **Kaplan-Meier method of survival analysis clearly showed a significant difference by group (log rank p<0.001) such that more of the cobinamide treated animals survived compared to the untreated animals.** Mean systolic blood pressure 10 minutes post treatment was 101.20±17.06 mmHg for cobinamide treated animals vs 37.75±19.08 mmHg for control; 95% CI difference 2.94, 123.96.

**7. How may your findings benefit the Air Force?** Hydrogen sulfide is an attractive terrorism tool because of its high toxicity and ease with which it can be produced. Several potential antidotes have been proposed for hydrogen sulfide poisoning, but none have been completely successful. Our studies indicate that cobinamide can successfully reverse hydrogen sulfide poisoning in an animal model. We have also shown that cobinamide successfully reverses cyanide poisoning in an animal model. Moreover, cobinamide can be administered via the IM route making it an easy drug to deliver by first responders at any role of care.

**8. Number of Animals**

Projected Enrollment of Animals at the Beginning of Study: 62 (added 16 through amendments 1&4)

Actual Number of Animals Enrolled: 76

**9. Status of Animals Entered into the Protocol:** All animals used were in good health.

**10. Number of animals since last status report:**

|                                          | Number enrolled since last report | Total enrollment to date |
|------------------------------------------|-----------------------------------|--------------------------|
| Number of animals entered into the Study | 0                                 | 76                       |

**11. Status of Funds:** Our study was funded by the AF SGR. We had no budget deviations and all funds have been allocated for.

**12. Reason for Closure:** Objectives of the study were met.

**13. Specific Problems:** We completed 6 experiment animals treated with IM cobinamide and we had difficulty with resuscitating these animals. We expected that since the IV cobinamide worked so well, that the IM cobinamide would work almost as well. However, we were unsuccessful resuscitating these IM cobinamide treated animals despite varying the dose of cobinamide and timing of cobinamide administration. Because of this difficulty we obtained an amendment (#1) asking for 10 additional animals to further explore the IM dose of cobinamide to determine if it is being absorbed under these experimental conditions. With our initial IM model, 1/3 of the pigs survived. We worked toward improving the cobinamide formulation, which improved survival rate to 100%.

**14. Publications and Presentations:**

#### **Presentations**

2016 Oral presentation and poster at San Antonio Military Health System and Universities Research Forum (SURF) meeting in May 2016 at the University of Texas at San Antonio.

2017 Oral presentation and poster at the North American Congress of Clinical Toxicology meeting on October 11-15, 2017 in Vancouver, British Columbia at the Sheraton Vancouver Wall Centre.

These Presentations have been cleared by 59 CRD and Public Affairs.

#### **Publications:**

Bebarta VS, Garrett N, Brenner M, Mahon SB, Maddry JK, Boudreau S, Castaneda M, Boss GR. Efficacy of Intravenous Cobinamide Versus Hydroxocobalamin or Saline for Treatment of Severe Hydrogen Sulfide Toxicity in a Swine (*Sus scrofa*) Model. Academy of Emergency Medicine 2017 Sep;24(9):1088-1098. doi: 10.1111/acem.13213 [Electronic publication]

This publication has been cleared by the 59 CRD and Public Affairs

**15. Exceptional Achievements:** None

**16. Signature of Principal Investigator:**

---

Joseph Maddry, MD, Maj, USAF, MC, FS  
Emergency Physician/Medical Toxicologist  
Director, USAF En route Care Research Center  
Director, Clinical Resuscitation, Emergency Sciences, and Toxicology  
59th MDW/ST Chief Scientists Office  
U.S. Army Institute of Surgical Research